For research use only
| Cat No. | ABC-X0322C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human FLT3 (F691L) BAF3 Cell Line is ideal for modeling drug resistance in FLT3-mutant leukemia and evaluating FLT3 inhibitor sensitivity in vitro.
Human FLT3 (F691L) BAF3 Overexpression Cell Line is engineered by introducing a human FLT3 mutant (F691L) gene into Ba/F3 cells using lentiviral transduction. The cell line is validated by qRT-PCR and maintained at low passage numbers (<P20). Target FLT3 is a receptor tyrosine kinase involved in hematopoietic stem cell proliferation. The F691L gatekeeper mutation confers resistance to multiple FLT3 inhibitors, making it a key target in relapsed acute myeloid leukemia (AML). AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0322C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model is used to evaluate FLT3 inhibitor resistance mechanisms and to develop next-generation FLT3-targeted therapies, particularly in drug-resistant AML contexts.